Insider Trading activities of Proteostasis Therapeutics, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Proteostasis Therapeutics, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Proteostasis Therapeutics, Inc. since year 2005. Table 2 shows the detailed insider transactions of Proteostasis Therapeutics, Inc. since 2005. The reporting company's ticker symbol is PTI. The reporting company's CIK number is 1445283.
The total value of stock buying since 2005 is $35,560,566.
The total value of stock sales since 2005 is $3,467,627.
The total value of stock option exercises since 2005 is $0.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Proteostasis Therapeutics, Inc. (PTI).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-03 0 $0 214,300 $2,841,677 0 $0
2017-02 0 $0 43,000 $625,950 0 $0
2016-12 687,567 $7,336,227 0 $0 0 $0
2016-11 818,247 $8,124,361 0 $0 0 $0
2016-09 992,306 $12,899,978 0 $0 0 $0
2016-02 900,000 $7,200,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Proteostasis Therapeutics, Inc. insiders (PTI)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-03-13 Fmr Llc (Other) Sale 25,000 12.94 323,500
2017-03-10 Fmr Llc (Other) Sale 25,000 12.04 301,000
2017-03-09 Fmr Llc (Other) Sale 4,300 11.90 51,152
2017-03-08 Fmr Llc (Other) Sale 25,000 12.10 302,500
2017-03-07 Fmr Llc (Other) Sale 35,000 13.13 459,550
2017-03-06 Fmr Llc (Other) Sale 25,000 13.31 332,750
2017-03-03 Fmr Llc (Other) Sale 20,000 13.63 272,600
2017-03-02 Fmr Llc (Other) Sale 25,000 14.30 357,625
2017-03-01 Fmr Llc (Other) Sale 30,000 14.70 441,000
2017-02-28 Fmr Llc (Other) Sale 15,000 14.47 217,050
2017-02-27 Fmr Llc (Other) Sale 15,000 14.65 219,750
2017-02-24 Fmr Llc (Other) Sale 13,000 14.55 189,150
2016-12-16 Berger Franklin M (Director) Buy 14,000 11.52 161,336
2016-12-15 Berger Franklin M (Director) Buy 26,000 10.99 285,636
2016-12-13 Cormorant Global Healthcare Master Fund, Lp Buy 21,301 10.98 233,948
2016-12-12 Cormorant Global Healthcare Master Fund, Lp Buy 100,000 10.79 1,079,000
2016-12-08 Cormorant Global Healthcare Master Fund, Lp Buy 21,819 10.93 238,481
2016-12-07 Cormorant Global Healthcare Master Fund, Lp Buy 22,598 10.74 242,702
2016-12-06 Cormorant Global Healthcare Master Fund, Lp Buy 24,648 10.89 268,317
2016-12-05 Cormorant Global Healthcare Master Fund, Lp Buy 89,271 10.78 962,607
2016-12-02 Cormorant Global Healthcare Master Fund, Lp Buy 150,000 10.48 1,571,400
2016-12-01 Cormorant Global Healthcare Master Fund, Lp Buy 41,984 10.11 424,584
2016-11-29 Cormorant Global Healthcare Master Fund, Lp Buy 128,407 10.28 1,319,510
2016-11-23 Cormorant Global Healthcare Master Fund, Lp Buy 180,500 11.02 1,989,290
2016-11-22 Cormorant Global Healthcare Master Fund, Lp Buy 69,500 11.08 769,851
2016-11-21 Cormorant Global Healthcare Master Fund, Lp Buy 111,863 11.64 1,302,644
2016-11-07 Cormorant Global Healthcare Master Fund, Lp Buy 231,700 8.69 2,012,546
2016-11-04 Cormorant Global Healthcare Master Fund, Lp Buy 76,000 7.68 583,756
2016-11-03 Cormorant Global Healthcare Master Fund, Lp Buy 20,277 7.24 146,764
2016-09-14 Berger Franklin M (Director) Buy 69,230 13.00 899,990
2016-09-14 Sandell Scott D (10% Owner) Buy 461,538 13.00 5,999,994
2016-09-14 Barrett M James (Director) Buy 461,538 13.00 5,999,994
2016-02-17 Perrigo Science One Ltd. Buy 125,000 8.00 1,000,000
2016-02-17 Berger Franklin M (Director) Buy 25,000 8.00 200,000
2016-02-17 Novartis Ag (10% Owner) Buy 375,000 8.00 3,000,000
2016-02-17 Fmr Llc (Other) Buy 375,000 8.00 3,000,000

Insider trading activities including stock purchases, stock sales, and option exercises of PTI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Proteostasis Therapeutics, Inc. (symbol PTI, CIK number 1445283) see the Securities and Exchange Commission (SEC) website.